Capital Grand Est

Superbranche is a biotechnology company specializing in the early detection and treatment of metastases. It develops therapeutic and diagnostic applications using nanotechnological provisions, aiming to improve accessibility and enable early tumor detection.

Keey Aerogel is a specialized manufacturer of silica aerogel, utilizing a closed-loop process that recycles construction waste, carbon dioxide, and ethanol. The company focuses on the valorization of silica-containing materials from construction and demolition activities, aiming to create energy-efficient building solutions and materials for various industrial applications. By producing this innovative nanoporous material, Keey Aerogel provides effective thermal insulation in ambient conditions, contributing to sustainability in construction and refurbishment projects.

Cixten is a technology company that specializes in recycling low-temperature waste heat from various industrial processes. It achieves this by harnessing the unique properties of supercritical CO2, converting the waste heat into usable energy forms such as electricity, compressed gas, or thermal upgrades, as per the specific requirements of its clients. This process not only helps businesses reduce their reliance on traditional energy sources but also contributes to a more sustainable and efficient use of energy.

Sirfull is a French software company specializing in welding quality management and equipment life cycle solutions. It offers VDB for welding quality control and technical documentation, IRM for collaborative industrial equipment inspection, monitoring, and risk management. The company serves manufacturers across various industries, providing services as Software-as-a-Service or PC/server installation.

Rhythm Diagnostic Systems is a healthcare technology company specializing in remote patient monitoring solutions. Its primary product, MultiSense®, enables continuous monitoring of patients' physiological parameters, both in hospitals and at home, aiming to improve patient pathways and enhance care efficiencies. The company serves primarily hospitals and institutions seeking to optimize patient care and reduce hospital stays. It generates recurring revenues through a 'fee for service' business model and offers additional services to support healthcare professionals in effectively using its technology.

Exeliom is a clinical-stage biopharmaceutical company based in Dijon, France, focused on developing innovative microbial therapies that utilize commensal bacteria as therapeutic agents. Founded in 2016, Exeliom aims to unlock the therapeutic potential of gut microbiota to enhance health and longevity. The company specializes in creating a new class of medicines known as Live Biotherapeutics, which are designed to deliver microbiome-based immunotherapy for conditions such as inflammatory bowel diseases and cancer, with an initial focus on Crohn's Disease. By harnessing the role of microbiota in the immune system, Exeliom strives to provide patients with advanced treatments that improve their quality of life.

Braintale develops and distributes digital tools for diagnosing and prognosing brain injuries. Its platform analyzes magnetic resonance imaging reports to help healthcare professionals predict patient trajectories, including the likelihood of coma and the need for intensive care after severe traumatic brain injury, cardiac arrest, or hemorrhagic stroke. Built on more than 15 years of clinical development, the company aims to translate medical insights into accessible decision-support for hospitals and patients. Founded in 2018 and based in Paris, France, Braintale focuses on improving neurological care through evidence-based, easy-to-use digital solutions.

Odimma is a biotech company specializing in precision medicine aimed at developing personalized cancer immunotherapy solutions. The company has created an innovative immunotherapy drug that harnesses a unique platform, integrating three specific immune components designed to work together with the patient's immune system. When administered, this approach aims to induce and enhance immune responses, providing patients with the potential to eliminate tumors while minimizing adverse side effects. Through its focus on personalized treatment strategies, Odimma seeks to improve outcomes for cancer patients by tailoring therapies to individual needs.

Miraxess is a French technology company that develops a plug‑in device called the Mirabook, which extends a smartphone into a full‑featured laptop. The device connects to the phone, providing a larger display, keyboard, and mouse input, thereby enabling users to perform work and entertainment tasks with greater productivity and comfort. By converting mobile phones into portable computing platforms, Miraxess offers a mobile convergence solution that addresses the growing reliance on smartphones for daily digital needs.